Antibiotic-Mediated Modulations of Outer Membrane Vesicles in Enterohemorrhagic Escherichia coli O104:H4 and O157:H7
暂无分享,去创建一个
[1] A. Mellmann,et al. Host cell interactions of outer membrane vesicle-associated virulence factors of enterohemorrhagic Escherichia coli O157: Intracellular delivery, trafficking and mechanisms of cell injury , 2017, PLoS pathogens.
[2] L. Hartling,et al. Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] A. Charlett,et al. Disease severity of Shiga toxin-producing E. coli O157 and factors influencing the development of typical haemolytic uraemic syndrome: a retrospective cohort study, 2009–2012 , 2016, BMJ Open.
[4] Hideo Tanaka,et al. A role for fosfomycin treatment in children for prevention of haemolytic-uraemic syndrome accompanying Shiga toxin-producing Escherichia coli infection. , 2015, International journal of antimicrobial agents.
[5] Björn Kemper,et al. Virulence from vesicles: Novel mechanisms of host cell injury by Escherichia coli O104:H4 outbreak strain , 2015, Scientific Reports.
[6] B. Devreese,et al. The effect of imipenem and diffusible signaling factors on the secretion of outer membrane vesicles and associated Ax21 proteins in Stenotrophomonas maltophilia , 2015, Front. Microbiol..
[7] C. Nakamura,et al. Structural Changes and Differentially Expressed Genes in Pseudomonas aeruginosa Exposed to Meropenem-Ciprofloxacin Combination , 2014, Antimicrobial Agents and Chemotherapy.
[8] M. Kuehn,et al. Stress-Induced Outer Membrane Vesicle Production by Pseudomonas aeruginosa , 2013, Journal of bacteriology.
[9] M. Christner,et al. Duration of fecal shedding of Shiga toxin-producing Escherichia coli O104:H4 in patients infected during the 2011 outbreak in Germany: a multicenter study. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] Ulrich C. Klostermeier,et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study , 2012, BMJ : British Medical Journal.
[11] A. Mellmann,et al. Effects of Antibiotics on Shiga Toxin 2 Production and Bacteriophage Induction by Epidemic Escherichia coli O104:H4 Strain , 2012, Antimicrobial Agents and Chemotherapy.
[12] B. Arulanandam,et al. Vesiculation from Pseudomonas aeruginosa under SOS , 2012, TheScientificWorldJournal.
[13] C. Hedberg,et al. Antibiotic Treatment of Escherichia coli O157 Infection and the Risk of Hemolytic Uremic Syndrome, Minnesota , 2012, The Pediatric infectious disease journal.
[14] M. Kuehn,et al. Contribution of bacterial outer membrane vesicles to innate bacterial defense , 2011, BMC Microbiology.
[15] Klaus Stark,et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. , 2011, The New England journal of medicine.
[16] A. Mellmann,et al. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. , 2011, The Lancet. Infectious diseases.
[17] J. Rothberg,et al. Prospective Genomic Characterization of the German Enterohemorrhagic Escherichia coli O104:H4 Outbreak by Rapid Next Generation Sequencing Technology , 2011, PloS one.
[18] P. Tarr,et al. Acute bloody diarrhea: a medical emergency for patients of all ages. , 2009, Gastroenterology.
[19] M. Kuehn,et al. Release of outer membrane vesicles by Gram-negative bacteria is a novel envelope stress response , 2007, Molecular microbiology.
[20] H. Karch,et al. Enterohaemorrhagic Escherichia coli in human medicine. , 2005, International journal of medical microbiology : IJMM.
[21] P. Tarr,et al. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome , 2005, The Lancet.
[22] G. Nair,et al. Release of Shiga Toxin by Membrane Vesicles in Shigella dysenteriae Serotype 1 Strains and In Vitro Effects of Antimicrobials on Toxin Production and Release , 2004, Microbiology and immunology.
[23] E. Seidman,et al. Pathogenesis of Shiga Toxin-Associated Hemolytic Uremic Syndrome , 2001, Pediatric Research.
[24] C. Harwood,et al. Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. , 2000, Emerging infectious diseases.
[25] Craig S. Wong,et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. , 2000, The New England journal of medicine.
[26] M. Waldor,et al. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. , 2000, The Journal of infectious diseases.
[27] Mary Jane Ferraro,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .
[28] H. Karch,et al. Strain-Specific Differences in the Amount of Shiga Toxin Released from Enterohemorrhagic Escherichia coli O157 following Exposure to Subinhibitory Concentrations of Antimicrobial Agents , 1998, European Journal of Clinical Microbiology and Infectious Diseases.
[29] D. Acheson,et al. Regulation of the Shiga-like toxin II operon in Escherichia coli , 1996, Infection and immunity.